Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.

Short-Term Limited Duration Insurance Plan Policies and Cancer Stage at Diagnosis

Open access

Abstract

Importance: Many short-term limited duration (STLD) insurance plans do not cover essential health benefits, such as cancer screenings, potentially delaying diagnoses. In October 2018, federal regulations loosened restrictions on STLD plans by extending the allowable duration from 3 months to 36 months. States expanded, restricted, or eliminated the sale or terms of STLD plans, both prior to 2018 and afterwards. The association of state-level policies and late-stage cancer diagnosis is largely undocumented. Objective: To examine associations of state-level policies regarding STLD plans and late-stage cancer diagnosis before and after the 2018 federal rule. Design, Setting, and Participants: This cross-sectional study included adults aged 18 to 64 years newly diagnosed with cancer (January 2016 to February 2020) in 47 states and the District of Columbia from the National Cancer Database. Patients were grouped by state-level STLD plan policies: (1) states continuously prohibited STLD plans before and after 2018; (2) states stopped offering STLD plans after 2018; (3) states allowed the sale of STLD plans with additional restrictions to the 2018 federal rules; (4) states with no additional STLD regulation. Difference-in-differences analyses were conducted to evaluate changes in late-stage diagnoses (stages III/IV) pre-2018 (January 2016 to June 2018) and post-2018 (January 2019 to February 2020) for groups 2, 3, and 4 vs group 1 for all cancers combined and for 5 common cancers, adjusting for sociodemographic factors (age group, sex, metropolitan status, zip code-level poverty), diagnosis year, and state random effect. All analyses were performed from May 2023 to January 2025. Exposures: State-level STLD plan policies. Main Outcomes and Measures: Change in percentages of late-stage cancer diagnosis. Results: Among 1 289 366 adults newly diagnosed with cancer (mean [SD] age, 53 [9.2] years; 536 514 [41.6%] female; 73 061 [5.7%] Hispanic, 110 564 [8.6%] non-Hispanic Asian and Pacific Islander and other, 172 246 [13.4%] non-Hispanic Black, 921 722 [71.5%] non-Hispanic White), 604 882 (46.9%) were from group 4 states (no additional STLD regulations). Group 4 had a net increase of 0.76 (95% CI, 0.22-1.29) percentage points (P = .01) and group 3 (some STLD regulations) had a net increase of 0.84 (95% CI, 0.26-1.42) percentage points (P = .005) in late-stage diagnoses compared with group 1 (continuously prohibited STLD plans). Similar patterns were observed for female breast and colorectal cancers. Conclusions and Relevance: In this cross-sectional study of state-level policies regarding STLD plans and late-stage cancer diagnosis, loosened federal restrictions on STLD plans in 2018 were associated with a net increase in late-stage cancer diagnoses in states without or with inadequate regulatory protections, underscoring the critical role of state policies in regulating STLD plans.

Overview

CoChat Summary

TL;DR

In a cross-sectional difference-in-differences study of 1,289,366 adults aged 18 to 64 years newly diagnosed with cancer from January 2016 to February 2020, the 2018 federal rule loosening short-term limited duration (STLD) insurance restrictions was associated with increased late-stage cancer diagnoses in states with no or some STLD regulations compared with states continuously prohibiting STLD plans. No significant change was seen in states that banned or stopped offering STLD plans after 2018.

Key findings

  • Compared with group 1 states (continuously prohibited STLD plans), adjusted difference-in-differences estimates showed a net increase in late-stage diagnosis of 0.76 percentage points (95% CI, 0.22-1.29; P = .01) in group 4 states (no additional STLD regulations) and 0.84 percentage points (95% CI, 0.26-1.42; P = .005) in group 3 states (some STLD regulations); group 2 states (banned/stopped offering STLD plans after 2018) had no significant change (0.45 percentage points; 95% CI, −0.22 to 1.12; P = .19).
  • By cancer site, group 3 had significant increases versus group 1 for colorectal cancer (2.55 percentage points; 95% CI, 0.59-4.52; P = .01) and prostate cancer (2.88 percentage points; 95% CI, 1.36-4.40; P < .001); group 4 had significant increases for female breast cancer (1.01 percentage points; 95% CI, 0.22-1.79; P = .01) and prostate cancer (3.27 percentage points; 95% CI, 1.86-4.68; P < .001).
  • Late-stage diagnosis percentages decreased after 2018 in all state groups; a falsification test among adults aged 66 to 70 years was generally statistically nonsignificant, and sensitivity analyses yielded similar results.

Methods

  • Cross-sectional quasi-experimental difference-in-differences study using the National Cancer Database, a hospital-based registry capturing approximately 72% of newly diagnosed cancer cases in the US; included 1,289,366 adults aged 18 to 64 years with stageable cancer diagnosed January 1, 2016, to February 29, 2020, from 47 states and the District of Columbia, excluding 3 states with policy/availability discrepancies and diagnoses after February 2020 due to COVID-19 disruptions.
  • Patients were categorized into 4 groups by state STLD policies as of February 2020: group 1 continuously prohibited STLD plans (control); group 2 banned or had restrictions leading insurers to stop offering STLD plans after the 2018 federal rule; group 3 had some additional STLD regulations; group 4 had no additional regulation beyond the federal rule. Primary outcome was late-stage diagnosis (stages III/IV).
  • Linear probability difference-in-differences models adjusted for age group, sex, metropolitan status, zip code–level poverty, diagnosis year, and state random effect; parallel trends were assessed, and sensitivity analyses restricted to recommended screening ages and further adjusted for zip code–level education and state-level uninsured rate.

Limitations

  • Stated in the paper: the NCDB is hospital-based rather than population-based; private insurance plan type and whether individuals had STLD coverage were unavailable; melanoma coverage in NCDB was relatively low (52%); the study reports associations rather than causality; other policies and programs (eg, NBCCEDP), state implementation/enforcement of STLD rules, AJCC 8th edition implementation, and unmeasured individual-level income and employment status could affect findings; data on total STLD plans and enrollees are limited.
  • Evident from the design: the cross-sectional observational structure cannot establish causality, and state policy groups defined as of February 2020 may not capture within-period timing, enforcement, or individual-level exposure to STLD plans, so exposure misclassification and residual confounding are possible.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2025.1075

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure. Short-Term Limited Duration (STLD) Insurance Plan Policies Before and After October 2018 Federal Rule aGroup 1 included states continuously prohibiting STLD plans during the study period: New York, New Jersey, Massachusetts, Rhode Island, and Vermont. bGroup 2 included states banning STLD plans or having restrictions that led insurers to stop offering STLD plans after the 2018 federal rule: California, Connecticut, Hawaii, New Mexico, Colorado, and Maine. cGroup 3 included states with some additional regulation besides the 2018 federal rule: District of Columbia, Delaware, Illinois, Kansas, Maryland, Michigan, Minnesota, Missouri, North Dakota, New Hampshire, Nevada, Oregon, South Carolina, Washington, and Wisconsin. dGroup 4 included states with no additional regulation besides the 2018 federal rule: Alabama, Alaska, Arkansas, Arizona, Florida, Georgia, Iowa, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Nebraska, North Carolina, Oklahoma, Pennsylvania, Tennessee, Utah, Texas, Virginia, West Virginia, and Wyoming.
Figure. Short-Term Limited Duration (STLD) Insurance Plan Policies Before and After October 2018 Federal Rule aGroup 1 included states continuously prohibiting STLD plans during the study period: New York, New Jersey, Massachusetts, Rhode Island, and Vermont. bGroup 2 included states banning STLD plans or having restrictions that led insurers to stop offering STLD plans after the 2018 federal rule: California, Connecticut, Hawaii, New Mexico, Colorado, and Maine. cGroup 3 included states with some additional regulation besides the 2018 federal rule: District of Columbia, Delaware, Illinois, Kansas, Maryland, Michigan, Minnesota, Missouri, North Dakota, New Hampshire, Nevada, Oregon, South Carolina, Washington, and Wisconsin. dGroup 4 included states with no additional regulation besides the 2018 federal rule: Alabama, Alaska, Arkansas, Arizona, Florida, Georgia, Iowa, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Nebraska, North Carolina, Oklahoma, Pennsylvania, Tennessee, Utah, Texas, Virginia, West Virginia, and Wyoming.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 14 Not checked · 31 Own results and interpretations

12 more claims

Create a free account to see all 45 claims and to verify the 15 references still open.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Cited by

Metadata

Authors
Yang, N. N., Zhao, J., Barnes, J. M., Kirchhoff, A. C., Chino, F., Yabroff, K. R., & Han, X.
Affiliations
  • American Cancer Society (US)
  • Washington University in St. Louis (US)
  • University of Utah (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Yang, Nuo Nova
Venue
JAMA Network Open
Published
2025-03-18
Volume
8
Issue
3
Pages
e251075
ISSN
2574-3805 (ISSN-L)
OpenAlex
W4408571974
Cited by
1
References
10
Citations by year
2026: 1
FWCI
0.37
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • JAMA Network Open (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
state insurance policy, late-stage cancer diagnosis, cancer stage at diagnosis, essential health benefits, cancer screening, health insurance coverage, state insurance regulation, newly diagnosed cancer, health disparities, racial and ethnic disparities, low-income adults, health policy evaluation, National Cancer Database, United States states
MeSH terms
Adolescent, Adult, Cross-Sectional Studies, Female, Humans, Insurance, Health, Male, Middle Aged, Neoplasm Staging, Neoplasms, State Government, Time Factors, United States, Insurance Coverage, Early Detection of Cancer, Young Adult, Delayed Diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.